Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 8/2015

01.08.2015 | Bipolar Disorders (W Coryell, Section Editor)

Management of Adverse Effects of Mood Stabilizers

verfasst von: Andrea Murru, Dina Popovic, Isabella Pacchiarotti, Diego Hidalgo, Jordi León-Caballero, Eduard Vieta

Erschienen in: Current Psychiatry Reports | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Mood stabilizers such as lithium and anticonvulsants are still standard-of-care for the acute and long-term treatment of bipolar disorder (BD). This systematic review aimed to assess the prevalence of their adverse effects (AEs) and to provide recommendations on their clinical management. We performed a systematic research for studies reporting the prevalence of AEs with lithium, valproate, lamotrigine, and carbamazepine/oxcarbazepine. Management recommendations were then developed. Mood stabilizers have different tolerability profiles and are eventually associated to cognitive, dermatological, endocrine, gastrointestinal, immunological, metabolic, nephrogenic, neurologic, sexual, and teratogenic AEs. Most of those can be transient or dose-related and can be managed by optimizing drug doses to the lowest effective dose. Some rare AEs can be serious and potentially lethal, and require abrupt discontinuation of medication. Integrated medical attention is warranted for complex somatic AEs. Functional remediation and psychoeducation may help to promote awareness on BD and better medication management.
Literatur
1.
Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–82.PubMed
2.
Nivoli AM et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011;129(1–3):14–26.PubMed
3.
Nivoli AM et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2012;140(2):125–41.PubMed
4.••
Grunze H et al. WFSBP task force on treatment guidelines for bipolar disorders. The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219. Exhaustive clinical guidelines for the long-term treatment of the disorder and specific recommendations on both predominantly depressed and predominantly manic patients.PubMed
5.
Yatham LN et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.PubMed
6.
NICE clinical guidelines 38. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, update 2014.
7.
Nivoli AM et al. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology. 2010;62(1):27–35.PubMed
8.
Cipriani A et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.PubMed
9.
Geddes JR et al. BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375:385–95.PubMed
10.
Cipriani A et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2013;10:CD003196.PubMed
11.
Popovic D et al. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand. 2014;129(5):366–74.PubMed
12.
Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67:25–30.PubMed
13.
Young AH, Grunze H. Physical health of patients with bipolar disorder. Acta Psychiatr Scand Suppl. 2013; (442):3–10.
14.
Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–29.PubMed
15.
Velligan DI et al. Expert consensus panel on adherence problems in serious and persistent mental illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1–46.
16.
Moher D, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
17.
Stoner SC et al. Historical review of carbamazepine for the treatment of bipolar disorder. Pharmacotherapy. 2007;27(1):68–88.PubMed
18.
Khor AH et al. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia. 2014;55(11):e120–124.PubMed
19.
Verrotti A et al. Anticonvulsant drugs and hematological disease. Neurol Sci. 2014;35(7):983–93.PubMed
20.
Ishikita T et al. Carbamazepine-induced thrombocytopenia defined by a challenge test. Am J Hematol. 1999;62(1):52–5.PubMed
21.
Handoko KB et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. 2006;47(7):1232–6.PubMed
22.
Tohen M et al. Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry. 1991;52(12):496–8.PubMed
23.
Durelli L et al. Cardiac side effects of phenytoin and carbamazepine. A dose-related phenomenon? Arch Neurol. 1985;42(11):1067–8.PubMed
24.
Verrotti A et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia. 2011;52(2):199–211.PubMed
25.
Rubin RL. Drug-induced lupus. Expert Opin Drug Saf. 2015;14(3):361–78.PubMed
26.
27.
Pickrell WO et al. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84(7):796–9.PubMed
28.
Chuang YC et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53(1):120–8.PubMed
29.
Arif H et al. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14(1):202–9.PubMed
30.
Bromley RL et al. Cognitive and neurodevelopmental effects of antiepileptic drugs. Epilepsy Behav. 2011;22(1):9–16.PubMed
31.
Harden CL. Sexual dysfunction in women with epilepsy. Seizure. 2008;17(2):131–5.PubMed
32.
Holmes LB et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68(10):1275–81.PubMed
33.
Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63 Suppl 4:42–55.PubMed
34.
Velez-Ruiz NJ, Meador KJ. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf. 2015.
35.
Letmaier M et al. Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol. 2012;15(6):739–48.PubMed
36.
Reinares M et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol. 2013;16(2):485–96.PubMed
37.
Carvalho AF, et al. Treatment implications of predominant polarity and the polarity index: a comprehensive review. Int J Neuropsychopharmacol. 2014.
38.
Seo HJ et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol. 2011;34:39–47.PubMed
39.
Calabrese JR et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63(11):1012–9.PubMed
40.
Goodwin GM et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithiummaintenance in bipolar I disorder. J Clin Psychiatry. 2004;65(3):432–41.PubMed
41.
Daban C et al. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J Clin Psychopharmacol. 2006;26(2):178–81.PubMed
42.
Gil-Nagel A et al. Effect of lamotrigine on sexual function in patients with epilepsy. Seizure. 2006;15(3):142–9.PubMed
43.
Morrow J et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193–8.PubMedCentralPubMed
44.
Viguera AC et al. Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. J Clin Psychiatry. 2007;68 Suppl 9:29–33.PubMed
45.
Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry. 1994;164:149–52.PubMed
46.
Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs. 2011;25(4):289–98.PubMed
47.
Fyro B, et al. Serum lithium levels and side effects during administration of lithium carbonate and two slow release lithium preparations to human volunteers. Pharmacol Clin 1970; 236–240.
48.
Lydiard RB, Gelenberg AJ. Hazards and adverse effects of lithium. Ann Rev Med. 1982;33:327–44.PubMed
49.
Karniol IG et al. Acute and chronic effects of lithium chloride on physiological and psychological measures in normals. Psychopharmacology. 1978;57(3):289–94.PubMed
50.
Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol. 2004;5:3–8.PubMed
51.
Jafferany M. Lithium and psoriasis: what primary care and family physicians should know. Prim Care Companion J Clin Psychiatry. 2008;10(6):435–9.PubMedCentralPubMed
52.
Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med. 2006;119(6):478–81.PubMed
53.
Licht RW. Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther. 2012;18(3):219–26.PubMed
54.
Wingo AP et al. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry. 2009;70(11):1588–97.PubMed
55.
López-Jaramillo C et al. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry. 2010;71:1055–60.PubMed
56.
Tredget J et al. Effects of chronic lithium treatment on renal function. J Affect Disord. 2010;126(3):436–40.PubMed
57.
Bendz H et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010;77(3):219–24.PubMed
58.
McKnight RF et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721–8.PubMed
59.
Coresh J et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.PubMed
60.
Rej S et al. Prevalence and correlates of renal disease in older lithium users: a population-based study. Am J Geriatr Psychiatry. 2014;22(11):1075–82.PubMed
61.
Kupka RW et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry. 2002;51(4):305–11.PubMed
62.
Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:723–33.PubMed
63.
Bauer M et al. A. Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. J Affect Disord. 2007;104(1–3):45–51.PubMed
64.
Kraszewska A et al. A cross-sectional study of thyroid function in 66 patients with bipolar disorder receiving lithium for 10–44 years. Bipolar Disord. 2014. doi:10.​1111/​bdi.​12275.PubMed
65.
Albert U et al. Lithium-associated hyperparathyroidism and hypercalcaemia: a case-control cross-sectional study. J Affect Disord. 2013;151(2):786–90.PubMed
66.
Baştürk M et al. Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:315–22.PubMed
67.
El Khoury A et al. Decreased plasma prolactin release in euthymic lithium-treated women with bipolar disorder. Neuropsychobiology. 2003;48:14–8.PubMed
68.
Altinbas K et al. Electrocardiography changes in bipolar patients during long-term lithium monotherapy. Gen Hosp Psychiatry. 2014;36(6):694–7.PubMed
69.
Grover S et al. Sexual dysfunction in clinically stable patients with bipolar disorder receiving lithium. J Clin Psychopharmacol. 2014;34(4):475–82.PubMed
70.
71.
Yonkers KA et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161:608–20.PubMed
72.
Nguyen HT et al. Teratogenesis associated with antibipolar agents. Adv Ther. 2009;26(3):281–94.PubMed
73.
Baldessarini RJ et al. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord. 1999;1:17–24.PubMed
74.
Gerstner T et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47(7):1136–43.PubMed
75.
Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438–45.PubMed
76.
Luef GJ et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55(5):729–32.PubMed
77.
Dreifuss FE et al. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37(3):379–85.PubMed
78.
Okayasu H et al. Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report. BMC Psychiatry. 2014;14:93.PubMedCentralPubMed
79.
Pellock JM et al. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia. 2002;43(11):1421–4.PubMed
80.
Asconapé JJ et al. Valproate-associated pancreatitis. Epilepsia. 1993;34(1):177–83.PubMed
81.
Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. CNS Drugs. 2013;27(6):435–55.PubMed
82.
Petty SJ et al. Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study. Epilepsia. 2014;55(10):1551–7.PubMed
83.
Smith MC et al. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav. 2004;5(5):746–51.PubMed
84.
Hu X et al. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011;97(1–2):73–82.PubMed
85.
Tohen M et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69(11):1776–89.PubMed
86.
Geller B et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012;69:515–28.PubMed
87.
Nouzeilles M et al. Prospective evaluation of parkinsonism and tremor in patients treated with valproate. Parkinsonism Relat Disord. 1999;5(1–2):67–8.PubMed
88.
Jamora D et al. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22(1):130–3.PubMed
89.
Tomson T. Which drug for the pregnant woman with epilepsy? N Engl J Med. 2009;360(16):1667–9.PubMed
90.
Harden CL, American Academy of Neurology, American Epilepsy Society, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology subcommittee of the American academy of neurology and the american epilepsy society. Epilepsia. 2009;50(5):1237–46.PubMed
91.••
Meador KJ, NEAD Study Group, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–52. It is commonly assumed that babies exposed to antiepileptic drugs in utero are at risk for teratogenic effects, but impact of some antiepileptic drugs are observable in cognitive effects the long term.PubMedCentralPubMed
92.
Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384–90.PubMed
93.
Colom F, Vieta E, Sánchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194(3):260–5.PubMed
94.
Velligan DI et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16(5):306–24.PubMed
95.
Martinez-Aran A et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007;9(1–2):103–13.PubMed
96.
Rosa AR et al. Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J Affect Disord. 2013;150(1):29–36.PubMed
97.••
Torrent C et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013;170(8):852–9. A novel adjunctive intervention for bipolar disorder patients with cognitive impairment.PubMed
98.
Dias VV et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand. 2012;126(5):315–31.PubMed
99.
100.
Kaniwa N, Saito Y. The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Ther Adv Drug Saf. 2013;4(6):246–53.PubMedCentralPubMed
101.
Pacchiarotti I, et al. Hyperprolactinemia and medications for Bipolar Disorder: systematic review of a neglected issue in clinical practice. In press.
102.
Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol. 2008;24(10):562–70.PubMed
103.
Garber JR et al. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22:1200–35.PubMed
104.
Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Br J Psychiatry. 1999;175:336–9.PubMed
105.
Sobotka JL et al. A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP. 1990;24:1214–9.PubMed
106.
Asadi-Pooya AA, Ghetmiri E. Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. Epilepsy Behav. 2006;8:228–31.PubMed
107.
Vasudev K et al. Hematological effects of valproate in psychiatric patients: what are the risk factors? J Clin Psychopharmacol. 2010;30(3):282–5.PubMed
108.
Bowden CL et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. 2004;27(3):173–84.PubMed
109.
Swartz HA, Fagiolini A. Cardiovascular disease and bipolar disorder: risk and clinical implications. J Clin Psychiatry. 2012;73(12):1563–5.PubMed
110.
Goldstein BI et al. Excessive and premature new onset cardiovascular disease among adults with bipolar disorder in the USNESARC cohort. J Clin Psychiatry. 2015;76(2):163–9.PubMed
111.
McElroy SL. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry. 2009;70 Suppl 3:12–21.PubMed
112.
Chopra A et al. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry. 2012;34(3):290–8.PubMed
113.
Eyer F et al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol. 2005;25(4):376–80.PubMed
114.
Miodownik C et al. Lithium-induced tremor treated with vitamin B6: a preliminary case series. Int J Psychiatry Med. 2002;32(1):103–8.PubMed
115.••
Pacchiarotti I et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–62. Critical aspects in the use of antidepressant in bipolar disorder have been extensively reviewed. The Consensus produced a set of highly useful recommendations for the clinical treatment of bipolar depression.PubMedCentralPubMed
116.
Jefferson JW. A clinician’s guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry. 2010;71:1153–7.PubMed
117.
Schatzberg AF, Nemeroff CB. The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Washington, D.C: American Psychiatric Pub; 2009.
118.
Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr Scand. 2014;129(5):323–7.PubMed
119.
Saroukhani S et al. Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. Bipolar Disord. 2013;15(6):650–6.PubMed
120.
Langan J et al. Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy. BMC Psychiatry. 2013;13:234.PubMedCentralPubMed
Metadaten
Titel
Management of Adverse Effects of Mood Stabilizers
verfasst von
Andrea Murru
Dina Popovic
Isabella Pacchiarotti
Diego Hidalgo
Jordi León-Caballero
Eduard Vieta
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Current Psychiatry Reports / Ausgabe 8/2015
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-015-0603-z

Weitere Artikel der Ausgabe 8/2015

Current Psychiatry Reports 8/2015 Zur Ausgabe

Psychiatry in Primary Care (BN Gaynes, Section Editor)

The Promise of Biomarkers in Diagnosing Major Depression in Primary Care: the Present and Future

Psychiatry in the Digital Age (JS Luo, Section Editor)

Realizing the Potential of Mobile Mental Health: New Methods for New Data in Psychiatry

Military Mental Health (CH Warner, Section Editor)

A Review of the Use of Stellate Ganglion Block in the Treatment of PTSD

Substance Use and Related Disorders (F Levin and E Dakwar, Section Editors)

Understanding and Shifting Drug-Related Decisions: Contributions of Automatic Decision-Making Processes

Military Mental Health (CH Warner, Section Editor)

Complementary and Alternative Medicine Approaches in the Treatment of PTSD

Disaster Psychiatry: Trauma, PTSD, and Related Disorders (E Foa and A Asnaani, Section Editors)

Risk Factors for the Development of Psychopathology Following Trauma

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise